Changes to Moberg Pharma´s Management
25 juni, 08:00
Changes to Moberg Pharma´s Management
Following the announcement in Moberg Pharma’s interim report for the period January–March 2025, the company has conducted a review of its resource allocation. The need for resources in clinical development in particular has decreased, while the needs within commercialization is increasing as a result of ongoing and planned launches in Europe. As part of this transition, the company’s management team is being streamlined.
In connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon’s existing area of responsibility. The company’s medical expertise is secured through consultants. Following these changes, Moberg Pharma’s management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.
“We are entering a new phase where the focus is on maximizing the commercial potential of Terclara® in Europe. The new organization is a natural step to ensure that our resources are directed where they create the most value for continued growth. I would like to extend my sincere thanks to Anders Bröijersén and Robert Ehrl for their valuable contributions during the launch preparations of Terclara®. We wish them both the very best in their future ventures,” says Anna Ljung, CEO of Moberg Pharma AB.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
About this information
The information was submitted for publication, through the agency of the contact person set out above, on June 25th, 2025, at 8.00 am CEST.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).
Changes to Moberg Pharma´s Management
25 juni, 08:00
Changes to Moberg Pharma´s Management
Following the announcement in Moberg Pharma’s interim report for the period January–March 2025, the company has conducted a review of its resource allocation. The need for resources in clinical development in particular has decreased, while the needs within commercialization is increasing as a result of ongoing and planned launches in Europe. As part of this transition, the company’s management team is being streamlined.
In connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon’s existing area of responsibility. The company’s medical expertise is secured through consultants. Following these changes, Moberg Pharma’s management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.
“We are entering a new phase where the focus is on maximizing the commercial potential of Terclara® in Europe. The new organization is a natural step to ensure that our resources are directed where they create the most value for continued growth. I would like to extend my sincere thanks to Anders Bröijersén and Robert Ehrl for their valuable contributions during the launch preparations of Terclara®. We wish them both the very best in their future ventures,” says Anna Ljung, CEO of Moberg Pharma AB.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
About this information
The information was submitted for publication, through the agency of the contact person set out above, on June 25th, 2025, at 8.00 am CEST.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).
-1-992x558.webp&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
-992x558.webp&w=3840&q=75)
-1-160x160.jpg&w=3840&q=75)
Aktierekommendationer
-992x558.webp&w=3840&q=75)
Analyser
-160x160.jpg&w=3840&q=75)
Aktierekommendationer
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
